Hem › Non-Hodgkins lymfom › North Carolina › Durham
Kliniska studier för Non-Hodgkins lymfom i Durham, NC
16 studier för Non-Hodgkins lymfom söker deltagare vid platser i och runt Durham (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekryterarFas 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi bort
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekryterarFas 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi bort
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RekryterarObservationsstudie
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekryterarFas 3
- Duke Cancer Institute, Durham
DALY II USA/ MB-CART2019.1 for DLBCL
RekryterarFas 2
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekryterarObservationsstudie
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi bort
Registry of Older Patients With Cancer
RekryterarObservationsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi bort
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekryterarFas 1
- University of North Carolina, Chapel Hill · 10 mi bort
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekryterarFas 1/2
- Duke University Medical Center, Duke Cancer Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekryterarFas 4
- Duke University Medical Center, Durham
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekryterarFas 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
RekryterarFas 1
- Duke University, Durham
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekryterarFas 1
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi bort
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RekryterarObservationsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi bort
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RekryterarFas 1
- University of North Carolina, Chapel Hill · 10 mi bort
Non-Hodgkins lymfom-studier i andra städer
- New York City, NY31 studier
- Houston, TX31 studier
- Boston, MA26 studier
- Nashville, TN21 studier
- Philadelphia, PA20 studier
- Baldwin Park, CA19 studier
- Washington, DC18 studier
- Milwaukee, WI18 studier
- Chicago, IL18 studier
- Atlanta, GA18 studier
- Columbus, OH18 studier
- Dallas, TX17 studier
Andra studier i Durham
- Bröstcancer64 studier
- Cancer (alla typer)58 studier
- Icke-småcellig lungcancer39 studier
- Multipelt myelom37 studier
- Akut myeloid leukemi33 studier
- Metastaserande cancer33 studier
- Prostatacancer32 studier
- Lungcancer32 studier
- Kolorektal cancer28 studier
- Äggstockscancer27 studier
- Kronisk lymfatisk leukemi27 studier
- Hjärtsvikt26 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.